Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
298.667USD
-1.863-0.62%
Market hours （ET）Quotes delayed by 15 min
5.91BMarket Cap
38.92P/E TTM
More Details of Ligand Pharmaceuticals Inc Company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Ligand Pharmaceuticals Inc Info
Ticker SymbolLGND
Company nameLigand Pharmaceuticals Inc
IPO dateNov 18, 1992
CEODavis (Todd C)
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 18
Address555 Heritage Drive, Suite 200
CityJUPITER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33458
Phone18585507500
Websitehttps://www.ligand.com/
Ticker SymbolLGND
IPO dateNov 18, 1992
CEODavis (Todd C)
Company Executives of Ligand Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
116.79K
-3.57%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
40.34K
+2.07%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
30.32K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
27.37K
+0.06%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
10.14K
+8.25%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.19K
-26.25%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
5.54K
+11.79%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
--
--
Ms. Melanie J. Herman
Ms. Melanie J. Herman
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
116.79K
-3.57%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
40.34K
+2.07%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
30.32K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
27.37K
+0.06%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
10.14K
+8.25%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.19K
-26.25%
FAQs
Who are the top five shareholders of Ligand Pharmaceuticals Inc?
The top five shareholders of Ligand Pharmaceuticals Inc are: Mr. Jason M. Aryeh
How many institutions hold shares of Ligand Pharmaceuticals Inc (LGND)?
As of 2026Q1, 634 institutions hold shares of Ligand Pharmaceuticals Inc, with a combined market value of approximately 20.97M, accounting for 104.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -493867.00.
What is the biggest source of revenue for Ligand Pharmaceuticals Inc?
In 2026Q1, the Contract Revenue- Other business generated the highest revenue for Ligand Pharmaceuticals Inc, amounting to 66.87M and accounting for 24.94% of total revenue.